Introduction {#S1}
============

Lipid kinases phosphorylate selected positions on the inositol head group of phosphatidylinositol (PI) generating second messengers that regulate multiple processes in eukaryotic cells. Phosphatidylinositol 3,4,5-trisphosphate \[PI(3,4,5)P~3~ or PIP~3~\] generation from phosphatidylinositol 4,5-bisphosphate \[PI(4,5) P~2~ or PIP~2~\] by class I phosphoinositide 3-kinase (PI3K) following growth factor receptor (e.g., insulin receptor) stimulation is a widespread signaling reaction ([@R26]; [@R55]) regulating growth and development ([@R35]). The role of class I PI3K activation in response to insulin receptor signaling is evolutionarily conserved and has been widely studied in metazoans such as the fly, worm, and mammals ([@R4]). Several mechanisms ensure robust control of PIP~3~ levels and dynamics. Binding of the class I PI3K heterodimer to p-Tyr residues on adaptor proteins associated with activated receptors relieves the basal inhibition of the regulatory subunit (p85/50/55/60) on the catalytic subunit (p110) ([@R33]). Additionally, lipid phosphatases including PTEN, a 3-phosphatase, and SHIP2, a 5-phosphatase, can also remove PIP~3~ from intracellular membranes ([@R16]; [@R42]). Mutations in genes for any of these enzymes can be oncogenic or result in metabolic syndromes; e.g., loss of PTEN function or gain in class I PI3K activity results in tumor development ([@R51]; [@R18]), whereas loss of SHIP2 results in altered insulin sensitivity ([@R13]). Thus, the control of receptor-activated PIP~3~ levels is vital to the regulation of cell growth and metabolism.

PIP~2~ (phosphatidylinositol 4,5-bisphosphate), the substrate for PIP~3~ production, is mainly synthesized via the phosphorylation of position 5 of the inositol headgroup of phosphatidylinositol 4-phosphate (PI4P) by phosphatidylinositol 4 phosphate 5-kinases (PIP5K) ([@R52]). [@R45] later described another class of lipid kinases, the phosphatidylinositol 5 phosphate 4-kinases (PIP4K), that phosphorylate position 4 of phosphatidylinositol 5-phosphate (PI5P) to generate PIP~2~. The total cellular PIP~2~ mass does not drop upon loss of PIP4Ks, but levels of its preferred substrate, PI5P, are elevated ([@R23]; reviewed in [@R30]). In mammalian cells, three isoforms of PIP4Ks occur, viz PIP4K2A, PIP4K2B, and PIP4K2C, and vary widely in their *in vitro* enzymatic activity. The mouse knockout phenotypes for each of these genes suggest a role for PIP4Ks in regulating receptor tyrosine kinase and PI3K signaling. Deletions of *PIP4K2A* and *PIP4K2B* slow down tumor growth in *p53*^−/−^ mice ([@R17]); depletion of PIP4K2C results in excessive T cell activation ([@R49]), and loss of *PIP4K2B* in mice results in hyper-responsiveness to insulin and a progressive loss of body weight in adults ([@R31]). Previous studies have linked *PIP4K2B* to insulin and PI3K signaling. Overexpression of PIP4K2B in CHO-IR cells (expressing extremely low levels of endogenous PIP4K2B) reduces insulin-stimulated PIP~3~ production ([@R9]). Similarly, acute doxycycline-induced overexpression of PIP4K2A in U-2 OS cells attenuates insulin-stimulated AKT activation, although PIP~3~ levels were not studied under these conditions ([@R27]). By contrast, a recent study reported that immortalized B cells carrying a deletion of *PIP4K2A* generate reduced levels of PIP~3~ following insulin stimulation ([@R8]). Thus, multiple lines of evidence link PIP4Ks and class I PI3K signaling during insulin stimulation, although the impact of PIP4K function on PIP~3~ levels remains unresolved.

Loss of the only *PIP4K* in *Drosophila* (mutants referred to as *dPIP4K^29^*) results in a larval growth deficit and developmental delay associated with an overall reduction in the levels of pS6K^T398^ and pAKT^S505^, both outputs of mechanistic target of rapamycin (mTOR) signaling. Enhancing mTOR complex 1 (TORC1) activity through pan-larval overexpression of its activator Rheb rescues the systemic growth defect in *dPIP4K^29^* ([@R15]; [@R23]). Since then, PIP4K2C has also been shown to regulate TORC1-mediated signaling in immune cells, and PIP4K2C enhances TORC1 outputs in Tsc1/2-depleted cells during starvation ([@R34]). mTOR signaling transduces multiple developmental and environmental cues like growth factor signaling, amino acid levels, and cellular ATP levels into growth responses ([@R57]). However, the relationship between PIP4K function, its role in regulating TORC1 activity, and class I PI3K signaling remains unclear.

During *Drosophila* larval development, a dramatic increase in body size occurs without increases in cell number but via an increase in cellular biomass of polyploid larval tissues such as the salivary gland and fat body ([@R10]). This form of growth is driven by ongoing insulin signaling mediated through the endocrine secretion of *Drosophila* insulin-like peptides (dILPs) from insulin-producing cells (IPCs) in the larval brain and their action on peripheral tissues through the single insulin receptor ([@R7]). Removal of the insulin receptor (*dInR*) ([@R50]) or the insulin receptor substrate (*chico*) ([@R5]) reduces growth and delays development through multiple mechanisms. In flies, salivary gland cell size can be tuned by enhancing cell-specific class I PI3K-dependent PIP~3~ production ([@R20]). In this study, we use salivary glands and fat body cells of *Drosophila* larvae to study the effect of dPIP4K on insulin receptor-activated class I PI3K signaling. We find that loss of *dPIP4K* leads to a cell-autonomous increase in the levels of basal and insulin-stimulated PIP~3~. dPIP4K acts at the plasma membrane to regulate the levels of PIP~3~ by modulating the class I PI3K activity. Moreover, the growth-promoting effects of the insulin signaling pathway are enhanced in the absence of dPIP4K. Finally, these cellular changes in insulin signaling have consequences on circulating sugar metabolism in larvae and alter their susceptibility to acquiring insulin resistance on a high-sugar diet (HSD). Altogether, we demonstrate dPIP4K as a physiologically important negative regulator of class I PI3K signaling during *Drosophila* insulin stimulation *in vivo*.

Results {#S2}
=======

Loss of PIP4K Elevates PIP~3~ Levels in *Drosophila* Cells {#S3}
----------------------------------------------------------

Plasma membrane PIP~3~ production upon class I PI3K activation is an essential early event during receptor tyrosine kinase signaling ([@R2]; [@R26]; [@R29]). We employed two methods to measure PIP~3~ levels from *Drosophila* larvae. First, we estimated PIP~3~ levels at the plasma membrane of individual cells by imaging salivary glands and fat body lobes of wandering third instar larvae expressing a PIP~3~-specific probe (GFP::PH-GRP1) ([@R6]). Salivary glands and fat body are organs composed of large insulin-responsive cells amenable to microscopy and *ex vivo* manipulations. Under basal conditions, the plasma membrane PIP~3~ in *dPIP4K^29^* salivary glands, as well as fat body cells, showed a small but significant elevation compared with wild type ([Figures 1Ai, 1Aii, 1Bi, and 1Bii](#F1){ref-type="fig"}). In an alternative approach, we quantified total PIP~3~ mass in whole larval lipid extracts using liquid chromatography coupled with mass spectrometry (LCMS) (see also [STAR Methods](#S10){ref-type="sec"} and [Figures S1D--S1F](#SD1){ref-type="supplementary-material"}). Unlike the single-cell PIP~3~ estimates from salivary glands and fat body cells, there was no significant difference in the total PIP~3~ levels measured using LCMS from wild-type and *dPIP4K^29^* larvae ([Figure 1C](#F1){ref-type="fig"}). Thus, the loss of dPIP4K leads to a basal elevation of PIP~3~ levels in cells, although total organismal PIP~3~ mass does not reflect the same, likely because of the heterogeneous effects of dPIP4K depletion in individual larval tissues.

During larval development in *Drosophila*, nutritional and developmental cues elicit the endocrine release of dILPs ([@R40]), which activate dInR triggering class I PI3K activation and PIP~3~ production. Therefore, the elevated PIP~3~ levels observed in *dPIP4K^29^* tissues could result from: (1) enhanced production and release of dILPs, (2) upregulation in insulin receptor levels, and (3) increase in insulin receptor activity or events downstream of receptor activation. To distinguish between these possibilities, we measured mRNA levels of *dILP2, 3, 5* (known to be transcriptionally regulated) ([@R7]) and found them relatively unchanged in *dPIP4K^29^* ([Figure S1A](#SD1){ref-type="supplementary-material"}). dILP2 immunoreactivity in the IPCs of the larval brain is indicative of the status of dILP release and is expected to be lower when more dILP2 is released into the hemolymph. Immunostaining of dILP2 in the IPCs was not lower in *dPIP4K^29^* compared with controls ([Figures S1Bi and S1Bii](#SD1){ref-type="supplementary-material"}), indicating that *dPIP4K^29^* larvae did not have enhanced levels of hemolymph dILP2. Further, *dInR* receptor mRNA levels in *dPIP4K^29^* were comparable with wild type, indicating that the levels of dInR activated by dILPs were also unlikely to be different between the two genotypes ([Figure S1C](#SD1){ref-type="supplementary-material"}). Collectively, we observed elevated PIP~3~ levels in cells lacking dPIP4K without evidence of increased humoral dILP secretion or insulin receptor levels.

Because the differences in PIP~3~ levels between *dPIP4K^29^* and control larvae were modest under basal conditions, we used an *ex vivo* assay to study the role of dPIP4K in cells during insulin stimulation. *Drosophila* cells respond to bovine insulin using signal transduction elements that are conserved with the canonical mammalian insulin signaling pathway ([@R32]). Imaging GFP::PH-GRP1 probe in salivary glands and fat body dissected from third instar larvae confirmed that *ex vivo* bovine insulin stimulation triggered a rise in plasma membrane PIP~3~ levels. Interestingly, insulin-stimulated (10 min, 10 μM) PIP~3~ levels in *dPIP4K^29^* were higher than in wild type ([Figures 1Di and 1Dii](#F1){ref-type="fig"}). Also, the difference in PIP~3~ levels between *dPIP4K^29^* and controls following insulin stimulation was noticeably greater than observed under basal conditions (compare [Figures 1Aii and 1Dii](#F1){ref-type="fig"}). Similarly, in fat body cells, PIP~3~ production increased over a 100-fold range of insulin concentrations. Whereas 100 nM insulin barely elicited an increase in PIP~3~ levels, we found fat body cells of *dPIP4K^29^* showed a larger rise in PIP~3~ levels compared with controls at higher concentrations of insulin ([Figures 1Ei--1Eiii](#F1){ref-type="fig"}). Further, total PIP~3~ mass analyzed from whole larval lipid extracts of insulin-stimulated larvae revealed that *dPIP4K^29^* larvae had significantly higher PIP~3~ levels than wild type ([Figures 1F](#F1){ref-type="fig"} and [S2B](#SD1){ref-type="supplementary-material"}). Thus, the modest elevation in the basal PIP~3~ levels seen in the absence of dPIP4K was further enhanced by *ex vivo* insulin stimulation.

Cell-Autonomous Control of Plasma Membrane PIP~3~ Levels by dPIP4K {#S4}
------------------------------------------------------------------

Because humoral dILP signals were not higher in *dPIP4K^29^*, we tested whether the elevated PIP~3~ levels in *dPIP4K^29^* larvae resulted from cell-autonomous changes in salivary gland cells. Reconstituting dPIP4K specifically in salivary glands of *dPIP4K^29^* larvae (*AB1\>dPIP4K^WT^; dPIP4K^29^*) resulted in a reduction of plasma membrane PIP~3~ levels ([Figure 2A](#F2){ref-type="fig"}). Further, we tested whether regulation of PIP~3~ levels by dPIP4K required its kinase activity by reconstituting a kinase-dead enzyme in *dPIP4K^29^*. A point mutation, D271A, in dPIP4K abolishes its kinase activity ([Figures S2D and S2E](#SD1){ref-type="supplementary-material"}, referred to as *dPIP4K^KinaseDead^* hereafter). *dPIP4K^KinaseDead^* rescued the elevated PIP~3~ levels back to those seen in controls ([Figure 2B](#F2){ref-type="fig"}). Salivary gland-specific depletion of dPIP4K (*AB1\>; dPIP4K^RNAi^*) ([Figure 2Ci](#F2){ref-type="fig"}) also increased insulin-stimulated PIP~3~ levels compared with controls ([Figure 2Cii](#F2){ref-type="fig"}).

Likewise, PIP~3~ levels were also elevated in *Drosophila* S2R^+^ cells where dPIP4K was depleted using double-stranded RNA (dsRNA) treatment (also reflected in the levels of all of the individual species) ([Figures 2Di, 2Dii](#F2){ref-type="fig"}, and [S2C](#SD1){ref-type="supplementary-material"}). Downstream effects of PIP~3~ signaling such as the pAKT^T342^ levels (the equivalent of mammalian pAKT^T308^ and phosphorylated by phosphoinositide-dependent kinase \[PDK1\]; [@R1]) and p-S6K^T398^, a target of TORC1, were also elevated in dPIP4K-depleted cells ([Figures 2Ei and 2Eii](#F2){ref-type="fig"}). Together, these observations suggest a cell-autonomous role for dPIP4K, independent of its ability to produce PI(4,5)P~2~, in limiting the levels of PIP~3~ and its downstream signaling during insulin stimulation.

PIP4K Functions at the Plasma Membrane to Regulate Insulin-Stimulated PIP~3~ Signaling {#S5}
--------------------------------------------------------------------------------------

We and others have seen PIP4Ks localize to multiple subcellular compartments ([@R12]; [@R23]). The substrate for PIP4K (i.e., PI5P) is also reported to occur on various organelle membranes ([@R47]). We sought to understand the sub-cellular compartment from which dPIP4K regulates plasma membrane PIP~3~ levels. We first established that the reduced TORC1 activity reported earlier in *dPIP4K^29^* mutants ([@R23]) did not drive the increase in PIP~3~ levels because of a loss of negative feedback activity ([Figure S3](#SD1){ref-type="supplementary-material"}). Next, we used unique signal sequences ([Figure 3A](#F3){ref-type="fig"}) to selectively target dPIP4K to distinct compartments including lysosomes, endomembranes, viz the endoplasmic reticulum (ER) and Golgi, and the plasma membrane ([Figures 3Bi--3Biv](#F3){ref-type="fig"}, compare localizations with the wild-type enzyme), and confirmed them to be enzymatically active ([Figures 3Ci and 3Cii](#F3){ref-type="fig"}). We then used salivary gland-specific reconstitution to test the ability of these constructs to revert the enhanced insulin-stimulated PIP~3~ production in *dPIP4K^29^*. Under these conditions, only the plasma membrane-targeted dPIP4K completely restored the elevated PIP~3~ levels in *dPIP4K^29^* to that of controls ([Figure 3F](#F3){ref-type="fig"}), whereas the lysosome-targeted ([Figure 3D](#F3){ref-type="fig"}) and endomembrane dPIP4K ([Figure 3E](#F3){ref-type="fig"}) failed to do so. Overexpression of plasma-membrane-targeted dPIP4K in wild-type salivary glands phenocopies overexpression of wild-type dPIP4K in suppressing insulin-stimulated PIP~3~ levels ([Figure 3G](#F3){ref-type="fig"}).

We compared the effect of overexpressing a human PIP4K2B with a CAAX-motif at its C terminus that localizes it to the plasma membrane against wild-type PIP4K2B in CHO-IR cells (compare localizations in [Figure 3Hi](#F3){ref-type="fig"}). In these cells, overexpression of PIP4K2B reduces the levels of pAKT^T308^, a downstream effect of PIP~3~-dependent signaling during insulin stimulation ([@R9]). Consistent with our findings in *Drosophila* cells, serum-starved CHO-IR cells transiently overexpressing either PIP4K2B::eGFP or PIP4K2B::mCherry^CAAX^ showed a small but significant reduction in pAKT^T308^ levels upon insulin stimulation ([Figure 3Hii](#F3){ref-type="fig"}). In fact, this decrease was achieved for PIP4K2B::mCherry^CAAX^ despite much lower levels of expression compared with the wild-type protein. Thus, our results suggest that plasma-membrane-localized PIP4K is sufficient to limit PIP~3~ levels and downstream signaling during insulin stimulation.

dPIP4K Alters PIP~3~ Turnover by Limiting Class I PI3K Activity {#S6}
---------------------------------------------------------------

To observe real-time PIP~3~ dynamics upon insulin stimulation, we developed a live-imaging assay using the GFP::PH-GRP1 probe in salivary gland cells. Key reactions involved in this process and the assay protocol are depicted in [Figures 4Ai and 4Aii](#F4){ref-type="fig"}, respectively. The dynamics of PIP~3~ turnover show three phases: (1) insulin-stimulated increase in PIP~3~ levels upon PI3K activation with relatively lower phosphatase activity (rise); (2) PIP~3~ levels achieve a steady state as the opposing kinase and phosphatase activities balance each other (steady state); and (3) wortmannin inactivates PI3K, whereas phosphatases remain active, leading to a fall in PIP~3~ levels (decay) ([Figure 4Bi](#F4){ref-type="fig"}). Class I PI3K inhibition was effective and specific as wortmannin abolished insulin-stimulated PIP~3~ production in contrast with addition of just the vehicle (DMSO) ([Figures 4Bii and 4Biii](#F4){ref-type="fig"}).

Using this assay, we observed that loss of dPIP4K resulted in higher steady-state levels of PIP~3~ in salivary gland cells compared with controls ([Figure 4C](#F4){ref-type="fig"}), and overexpression of dPIP4K ([Figure 4D](#F4){ref-type="fig"}) resulted in lower steady-state levels of PIP~3~, consistent with our earlier results from fixed salivary glands ([Figures 1Dii](#F1){ref-type="fig"} and [3G](#F3){ref-type="fig"}). Analysis of the rate of change in PIP~3~ levels during the initial rise phase clearly revealed enhanced PIP~3~ production rates in *dPIP4K^29^* following insulin stimulation and conversely reduced rates of PIP~3~ production upon overexpression of dPIP4K ([Figure 4Ei](#F4){ref-type="fig"}). In a similar analysis of the decay phase (i.e., upon class I PI3K inactivation), the rate of decay in PIP~3~ levels was marginally slower in dPIP4K-depleted cells and even slower in dPIP4K-overexpressing cells relative to controls ([Figure 4Eii](#F4){ref-type="fig"}). Initial studies with fixed insulin-stimulated salivary glands expressing the GFP::PH-GRP1 probe had failed to reveal these differences ([Figures S5Bi and S5Bii](#SD1){ref-type="supplementary-material"}). When the directions of changes in steady-state PIP~3~ levels and the enzyme activities are considered together, our findings imply that dPIP4K modulates the activity of both the kinases and phosphatases involved in PIP~3~ turnover, but appears to have a significantly greater effect on class I PI3K activity.

Loss of dPIP4K Enhances Physiological Outputs of Insulin Signaling *In Vivo* {#S7}
----------------------------------------------------------------------------

Insulin-stimulated production of PIP~3~ is closely linked to its downstream effects on cell physiology ([@R29]). We used salivary glands as a model organ to study changes in cell size ([@R20]; [@R23]) and sought to establish if the elevated PIP~3~ resulting from loss of dPIP4K impacts insulin signaling-dependent cell physiology. Insulin receptor signaling can autonomously control both cell size and proliferation ([Figure 5A](#F5){ref-type="fig"}) ([@R5]; [@R7]), although direct evidence for such regulation in salivary glands has not been reported. In proof of principle experiments, salivary gland-specific depletion of insulin receptor (*dInR*) levels through RNAi (*AB1\>InR^RNAi^*) reduced the average size of salivary gland cells without changing the number of cells ([Figures 5B and 5C](#F5){ref-type="fig"}). Conversely, dInR and Chico overexpression ([Figures 5Di and 5Ei](#F5){ref-type="fig"}) increased the average cell size, confirming the role of insulin signaling in regulating salivary gland cell size.

Next, we compared the effect of overexpressing insulin signaling components on wild-type and *dPIP4K^29^* salivary gland cells. Both *dInR* ([Figures 5Di and 5Dii](#F5){ref-type="fig"}) and insulin receptor substrate, *Chico* ([Figures 5Ei and 5Eii](#F5){ref-type="fig"}), increased salivary gland cell size in wild type and *dPIP4K^29^*. However, in both manipulations the increase in cell size elicited was significantly greater in *dPIP4K^29^* (*AB1\>dInR* \[or *Chico*\]*; dPIP4K29*) compared with wild-type cells (*AB1\>dInR* \[or *Chico*\]) ([Figure 5G](#F5){ref-type="fig"}). If PIP4K acted at the plasma membrane to limit PIP~3~ production *in vivo*, constitutively activating a component downstream of PIP~3~ synthesis would be expected to abolish the differences between wildtype and *dPIP4K^29^* cells. As predicted, unlike the *dInR* and *Chico* manipulations, expression of a constitutively active form of phosphoinositide-dependent kinase-1 (*PDK1*)-PDK1^A467V^, normally activated by PIP~3~-binding during insulin receptor activation ([@R43]; [@R46]), resulted in an equivalent cell size increase in wild-type and *dPIP4K^29^* salivary glands ([Figures 5Fi, 5Fii, and 5G](#F5){ref-type="fig"}).

If the insulin signaling pathway is indeed modulated by dPIP4K, it is expected to alter the physiological response of the animals to sugar intake. Larvae raised on a HSD have reduced body weight, developmental delay, and elevated levels of trehalose, the main circulating sugar in insect hemolymph. These phenotypes are reminiscent and equivalent to the development of insulin resistance in type II diabetes ([@R39]; [@R44]). Using this paradigm ([Figure S6A](#SD1){ref-type="supplementary-material"}), we found that wild-type larvae showed a delay in development (ca. of 9 days) when grown on HSD (1 M sucrose) through larval development, compared with animals grown on normal food (0.1 M sucrose), as seen by the time taken by a population of larvae to pupariate. Interestingly, *dPIP4K^29^* larvae grown on HSD were retarded to a much lesser magnitude (delay of only 5 days) compared with their growth on 0.1 M sucrose ([Figure S6B](#SD1){ref-type="supplementary-material"}). The levels of circulating trehalose in the hemolymph of wandering third instar larvae of *dPIP4K^29^* raised on normal food were ca. 40% lower compared with controls. But on HSD, while in the wild-type larvae, the circulating trehalose level had risen by ca. 25% compared to ND, in *dPIP4K^29^*, it essentially remained unchanged ([Figure S6C](#SD1){ref-type="supplementary-material"}).

Further, we modified and developed a shorter growth analysis protocol to test the requirement of the kinase activity of dPIP4K in the regulation of sugar metabolism. Here, larvae were exposed to the HSD only during the latter part of the third instar stage (depicted in [Figure S6D](#SD1){ref-type="supplementary-material"}). Under these conditions, control animals (*Act*\>) showed a delay of ca. 65 h when grown on HSD compared with those on normal food ([Figure 5H](#F5){ref-type="fig"}), whereas HSD-induced delay in *dPIP4K^29^* (*Act\>; dPIP4K^29^*) was only ca. 56 h ([Figure 5J](#F5){ref-type="fig"}). We then compared the ability of the wild-type and kinase-dead dPIP4K to revert the HSD-induced delay in *dPIP4K^29^* to those seen in control larvae. Only the wild-type *dPIP4K* transgene (*Act\>dPIP4K^WT^;dPIP4K^29^*) ([Figure 5I](#F5){ref-type="fig"}) restored the delay induced by HSD close to that seen in control animals, i.e., ca. 63 h, whereas the *kinase-dead* transgene (*Act\>dPIP4K^KinaseDead^; dPIP4K^29^*) was incapable of doing so, and the delay was similar to that seen in *dPIP4K^29^* ([Figure 5K](#F5){ref-type="fig"}). This indicates a role for the kinase activity of dPIP4K in supporting organismal control of sugar metabolism. Also, collectively our observations suggest that loss of dPIP4K modulates insulin receptor signaling *in vivo* and can confer partial protection against HSD-induced phenotypes.

Discussion {#S8}
==========

The core enzymes directly involved in PIP~3~ metabolism, a highly conserved element of signal transduction through many growth factor receptors, have been extensively studied. However, factors regulating their activity remain less understood. Some small GTPases (Ras, Rac) and G~βγ~ subunits are shown to be involved in the regulation of class I PI3K activity (reviewed in [@R25]). Our study identifies *dPIP4K* as a negative regulator of PIP~3~ levels during growth factor stimulation. This is evident from the elevated insulin-stimulated PIP~3~ levels seen in the mutants for the only PIP4K gene in *Drosophila* ([@R3]; [@R23]). Further, we have demonstrated that this function of dPIP4K is cell autonomous by negating a role for the humoral signals that impinge on insulin signaling and also by altering PIP~3~ levels through tissue-specific manipulations of dPIP4K in salivary glands and in dPIP4K-depleted *Drosophila* S2R^+^ cells. Many direct and indirect mechanisms have been proposed to regulate PIP~3~ levels. In an earlier study ([@R23]), it was reported that *dPIP4K^29^* larvae have reduced mTORC1 activity. Thus, a loss of TORC1-mediated feedback control on insulin receptor signaling, as demonstrated to occur in mammalian cells ([@R22]; [@R24]; [@R41]; [@R53]; [@R54]), may be the underlying reason for increased PIP~3~ levels in *dPIP4K^29^*. However, we ruled out this possibility by demon-strating that enhancing TORC1 activity was not able to revert elevated PIP~3~ levels in *dPIP4K^29^* salivary gland cells despite causing expected changes in cell size ([Figures S3A--S3G](#SD1){ref-type="supplementary-material"}). Our data clearly demonstrate that both TORC1 and dPIP4K are required to limit PIP~3~ levels in cells during insulin signaling.

In contrast with our previous study, where mTOR signaling read-outs like pS6K^T398^ and pAKT^s505^ levels were reduced in whole larval extracts of *dPIP4K^29^* ([@R23]), depleting dPIP4K in S2R^+^ cells led to a cell-autonomous increase in mTOR signaling downstream of insulin stimulation as seen by increased pAKT^T342^ as well as pS6K^T398^ levels ([Figure 2Eii](#F2){ref-type="fig"}). The discrepancy between the two observations is likely due to variable levels of TORC1 activation in various larval tissues and cell types in *dPIP4K^29^* (data not shown). mTOR activity is determined by multiple humoral signals in the context of a whole organism that may or may not require dPIP4K function in specific tissues ([@R14]; [@R19]). Our inability to observe an increase in basal PIP~3~ levels from whole larvae also hints toward this possibility.

Although PIP4K and its substrate, PI5P, occur on multiple sub-cellular compartments ([@R12]; [@R23]; [@R47]), we found that the plasma membrane-localized pool of PIP4K is sufficient to regulate PIP~3~ levels in cells from two different species: first in *Drosophila* cells, by rescuing elevated PIP~3~ levels in *dPIP4K^29^* by selective reconstitution with the plasma membrane-targeted enzyme; and second, in mammalian cells, by demonstrating a reduction in pAKT^308^ phosphorylation by overexpression of plasma membrane-localized PIP4K2B just as well as with wild-type PIP4K2B. These observations point to the evolutionarily conserved nature of this mechanism and are also consistent with a role for PIP4K in direct regulation of PIP~3~ independent of TORC1-mediated feedback control. Our live-imaging studies using chemical inhibition of class I PI3K also suggest that dPIP4K acts majorly by limiting the class I PI3K activity to regulate PIP~3~ levels with a marginal effect on the phosphatases. However, the exact mechanism by which it does so remains to be established.

Loss of PIP4K results in an elevation rather than a reduction in PIP~3~ levels, and a kinase-dead version of dPIP4K was also able to reduce PIP~3~ levels, which implies that the conversion of PI5P to PI(4,5)P~2~ by dPIP4K is not required to support the PIP~3~ production by class I PI3K. In addition to PIP~3~, we also measured the levels of PIP~2~, the substrate of class I PI3K for PIP~3~ production, using LCMS and live imaging of the PIP~2~-probe (PH-PLCδ::mCherry). Prior to insulin stimulation, resting PIP~2~ levels from larval tissues of *dPIP4K^29^* were no different from that of controls ([Figure S5Bi](#SD1){ref-type="supplementary-material"}). However, unlike wild-type cells where insulin stimulation did not change PIP~2~ levels ([Figures S5Bii and S5Di](#SD1){ref-type="supplementary-material"}), in dPIP4K-depleted cells, PIP~2~ levels rose substantially along with PIP~3~ levels ([Figures S5Bii and S5Dii](#SD1){ref-type="supplementary-material"} and trends observed in [Figure S5C](#SD1){ref-type="supplementary-material"}, although not statistically significant). These findings imply that during class I PI3K signaling, normal PIP4K function is also required to regulate PIP~2~ levels at the plasma membrane. It is unclear if the elevated PIP~2~ levels seen during insulin signaling directly underlie the elevated PIP~3~ levels in PIP4K-depleted cells. This seems unlikely because in almost all cell types and organisms studied so far, PIP~2~ levels are at least 500-fold more than PIP~3~ levels (recent example of PIP~2~ and PIP~3~ levels measured in mammalian cells; [@R36]), and therefore an active mechanism must exist to ensure generation of only a small amount of PIP~3~ from a much larger fraction of readily available PIP~2~. Moreover, PIP4K-depleted cells do not possess elevated basal levels of PIP~2~, which might support increased PIP~3~ production during stimulation. However, a link between the levels of the two lipids cannot be ruled out completely. Interestingly, a recent study has reported that cells depleted of PIP4K show elevated levels of PIP2 and PIP3; evidence is presented that the interaction of PIP5K, the enzyme that synthesizes the majority of PIP2 cells, is inhibited by its interaction with PIP4K ([@R56]).

Alternatively, elevated PI5P levels reported in PIP4K-depleted cells might mediate the increase in PIP~3~ levels by promoting class I PI3K activity. Previous studies have shown that levels of PI5P increase upon insulin stimulation and importantly, addition of exogenous PI5P can stimulate glucose uptake in a PI3K-dependent manner ([@R21]; [@R27]). In PIP4K-depleted cells, PI5P levels could rise unchecked at the plasma membrane during insulin stimulation, resulting in higher levels of PIP~3~. This model appears inconsistent with the tissue-specific rescue of elevated PIP~3~ levels in PIP4K-depleted cells by dPIP4K^KinaseDead^, which cannot produce PIP~2~ from PI5P because of its inability to hydrolyze ATP. However, when highly expressed ([Figure S2F](#SD1){ref-type="supplementary-material"}), such a rescue could simply occur through binding and sequestration of PI5P by dPIP4K^KinaseDead^. Identification and generation of a PI5P-binding mutant of PIP4K will be required to test this model. Interestingly, pan-larval expression of *dPIP4K^KinaseDead^* was unable to rescue the impact of dPIP4K depletion on the growth of larvae grown on HSD, whereas only the wild-type transgene could. This agrees with a recent study where the requirement of dPIP4K in regulating salivary gland cell size was seen to depend on the kinase activity of the enzyme ([@R37]). Future *in vivo* studies would require precise control of the expression and analysis of multiple tissues to clearly delineate kinase-dependent and -independent roles for PIP4K.

Elevated PIP~3~ levels, altered PI3K activity, and TORC1 activation in cells lacking dPIP4K would predict important physiological consequences on cell growth and sugar metabolism *in vivo*. Consistent with the idea of being a negative regulator, absence of dPIP4K enhanced the growth-promoting ability of insulin signaling components. Using a high-sugar-induced obesity and type II diabetes-like insulin resistance model ([@R39]), we found that *dPIP4K^29^* larvae appear partially resistant to the effects of a HSD, such as changes in hemolymph trehalose levels and developmental delay. These observations are reminiscent of phenotypes for PIP4K2B^−/−^ mice that also have a reduced adult body weight and clear blood glucose faster following a sugar bolus than controls ([@R31]). Our observation that dPIP4K controls sensitivity to insulin receptor activation at the plasma membrane suggests a molecular basis for the physiological phenotypes observed in *dPIP4K^29^* larvae and PIP4K2B^−/−^ mice. Such a mechanism may also explain the hyperactivation of the T cell receptor responses in mice lacking PIP4K2C ([@R49]), because the activation of class I PI3K is a key element of T cell receptor signal transduction. More generally, modulation of PIP4K function offers a mechanism to precisely regulate class I PI3K activity in the context of receptor tyrosine kinase signaling.

Star★Methods {#S10}
============

Key Resources Table {#S11}
-------------------

  -------------------------------------------------------------------------------------------------------------------------------------------
  REAGENT or RESOURCE                      SOURCE                                                              IDENTIFIER
  ---------------------------------------- ------------------------------------------------------------------- ------------------------------
  Antibodies                                                                                                   

  Rabbit polyclonal anti- α-actin          Sigma Aldrich                                                       A5060; RRID: AB_476738

  Rabbit polyclonal anti- dPIP4K           Generated for the lab by NeoBiolab (NeoScientific, Cambridge, MA)   N/A

  Rabbit polyclonal anti-GAPDH             Novus Biologicals                                                   IM-5143A; RRID: AB_1150416

  Rabbit polyclonal anti-PIP4KB            Cell Signaling Technology                                           9694; RRID: AB_2164572

  Rabbit polyclonal anti -- pAKT (T308)    Cell Signaling Technology                                           9275; RRID: AB_329828

  Rabbit polyclonal anti-AKT               Cell Signaling Technology                                           9272; RRID: AB_329827

  Rabbit polyclonal anti-pS6K (T398)       Cell Signaling Technology                                           9209: RRID: AB_2269804

  Rabbit polyclonal anti-pAKT1 (T342)      Abcam                                                               ab228808

  Rabbit polyclonal dILP2 antibody         Gift from Prof. Jan Veenstra, INCI, Uni. Of Bordeaux                N/A

  Chemicals                                                                                                    

  Drosophila Schneider's medium            GIBCO                                                               21720024

  Drosophila Schneider's medium            Himedia Labs.                                                       IML003A

  Fetal Bovine Serum                       GIBCO                                                               16000044

  Bovine Insulin                           SIGMA                                                               I6634

  Penicilllin-Streptomycin-Glutamine Mix   SIGMA                                                               G1146

                                           Himedia Labs.                                                       A007

  Megascript RNAi Kit                      AMBION, Life Technologies                                           AM1626

  Porcine Trehalase                        SIGMA                                                               T8778

  G418                                     Himedia Labs.                                                       TC025

  BODIPY® FL C12-Sphingomyelin             Life Technologies                                                   D-7711

  Fugene® 6                                Promega Corporation                                                 E2692

  Effectene                                QIAGEN                                                              301425

  17:0 20:4 PI(3,4,5)P3                    Avanti Polar Lipids                                                 LM 1906

  Glucose (GO) Assay Kit                   SIGMA                                                               GAGO-20

  Experimental Models: Cell Lines                                                                              

  CHO-IRA                                  Gift from Prof. Nicholas Webster,UCSD                               N/A

  S2R+ - ActGal4                           Gift from Satyajit Mayor Lab, NCBS.                                 N/A

  Experimental Models: Organisms/Strains                                                                       

  *Red Oregon R (ROR) - wildtype*          Bloomington                                                         2376

  *AB1-Gal4*                               Bloomington                                                         1824

  *UAS-dInR*                               Bloomington                                                         8262

  *UAS-Rheb*                               Bloomington                                                         9688

  *UAS-Rheb^RNAi^*                         Bloomington                                                         33966

  *UAS-TSC^RNAi^*                          Bloomington                                                         52931

  *P{tGPH}4*                               Bloomington                                                         8164

  *UAS-dPIP4K^RNAi^*                       Bloomington                                                         65891

  *Act5cGal4*                              Bloomington                                                         3953

  *UAS-4cPH-PLCδ1::mCherry*                Patrick Verstreken, VIB, Belgium.                                   N/A

  *dPIP4K29*                               Lab generated                                                       N/A

  *UAS-dPIP4K^wt^*                         Lab generated                                                       N/A

  *UAS-dPIP4K^KinaseDead^*                 Lab generated                                                       N/A

  *UAS-dPIP4K::eGFP*                       Lab generated                                                       N/A

  *UAS-dPIP4K::-mCherry-CAAX*              Lab generated                                                       N/A

  *UAS-Lysosomal-dPIP4K::eGFP*             Lab generated                                                       N/A

  *UAS-Endomembrane-dPIP4K::mCherry*       Lab generated                                                       N/A

  Oligonucleotides                                                                                             

  Ctrl (GFP)\_dsRNA_Fwd                    TAATACGACTCACTATAGGGATGG\                                           Ctrl (GFP)\_dsRNA_Fwd
                                           TGAGCAAGGGCGAGGAG                                                   

  Ctrl (GFP)\_dsRNA_Rev                    TAATACGACTCACTATAGGGCTTG\                                           Ctrl (GFP)\_dsRNA_Rev
                                           TACAGCTCGTCCATGCCG                                                  

  PIP4K dsRNA I F (DRSC17213)              TAATACGACTCACTATAGGGAAGTTTGA\                                       PIP4K dsRNA I F (DRSC17213)
                                           TTTAAAAGGTAGCAC                                                     

  PIP4K dsRNA I R (DRSC17213)              TAATACGACTCACTATAGGGCTCAGCG\                                        PIP4K dsRNA I R (DRSC17213)
                                           TGTCCATTAGTTT                                                       

  PIP4K dsRNA II F (DRSC39291)             TAATACGACTCACTATAGGGAAACA\                                          PIP4K dsRNA II F (DRSC39291)
                                           TGCCGTCACATTTCA                                                     

  PIP4K dsRNA II R (DRSC39291)             TAATACGACTCACTATAGGGGAGG\                                           PIP4K dsRNA II R (DRSC39291)
                                           TAACAGCGTTTTTCCG                                                    

  Software and Algorithms                                                                                      

  Volocity                                 Perkin Elmer Inc.                                                   Ver 5.5.1

  MultiQuant                               AB SCIEX                                                            Ver 1.1
  -------------------------------------------------------------------------------------------------------------------------------------------

Contact for Reagent and Resource Sharing {#S12}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Raghu Padinjat (<praghu@ncbs.res.in>).

Experimental Model and Subject Details {#S13}
--------------------------------------

### *Drosophila* strains and rearing {#S14}

Unless indicated, flies were grown on standard fly medium containing corn meal, yeast extract, sucrose, glucose, agar and antifungal agents. For all experiments, crosses were setup at 25°C in vials/bottles under non-crowded conditions. The stocks that were used in the study are described in the table of key resources. The fly media used had the following composition:

  Ingredients                         0.1 M sucrose   1 M sucrose
  ----------------------------------- --------------- -------------
  Corn flour                          80 g            80 g
                                                      
  D-Glucose                           20 g            20 g
                                                      
  Sugar                               40 g            342 g
                                                      
  Agar                                8 g(4g)         8 g
                                                      
  Yeast powder                        15 g            15 g
                                                      
  Propionic acid                      4 ml            4 ml
                                                      
  TEGO(Methyl parahydroxy benzoate)   0.7 g           0.7 g
                                                      
  Orthophosphoric acid                0.6 ml          0.6 ml

### Genotypes represented across figures {#S15}

[Figure 1](#F1){ref-type="fig"} - A, B, D and E. *tGPH* and *tGPH; dPIP4K^29^*. C and F. *ROR* and *dPIP4K^29^*.

[Figure 2](#F2){ref-type="fig"} - A. AB1Gal4, tGPH/+; dPIP4K^29^ and UAS-dPIP4K^WT^/+; AB1Gal4, tGPH/+; dPIP4K^29^ B. AB1Gal4, tGPH/+, AB1Gal4, tGPH/+; dPIP4K^29^ and UAS- dPIP4K^KinaseDead^/+; AB1Gal4, tGPH/+; dPIP4K^29^. C. AB1Gal4, tGPH/+ and UAS-dPIP4K^RNAi^/+; AB1Gal4, tGPH/+.

[Figure 3](#F3){ref-type="fig"} - D. AB1Gal4, tGPH /+ and AB1Gal4, tGPH /+; dPIP4K^29^ and AB1Gal4, tGPH /Lysosomal-dPIP4K::eGFP; dPIP4K^29^. E. AB1Gal4, tGPH /+ and AB1Gal4, tGPH /+; dPIP4K^29^ and AB1Gal4, tGPH /dPIP4K::mCherryEM; dPIP4K^29^. F. AB1Gal4, tGPH /+ and AB1Gal4, tGPH /+; dPIP4K^29^ and AB1Gal4, tGPH /dPIP4K::mCherryCAAX; dPIP4K^29^. G. AB1Gal4, tGPH /+ and UAS-dPIP4K^WT^ /+; AB1Gal4, tGPH /+ and AB1Gal4, tGPH /UAS-dPIP4K::mCherry^CAAX^.

[Figure 4](#F4){ref-type="fig"} - B(i-iii). AB1Gal4, tGPH/+. C. AB1Gal4, tGPH/+ and AB1Gal4, tGPH/+; dPIP4K^29^. D. AB1Gal4, tGPH/+ and UAS-dPIP4K^WT^/+; AB1Gal4, tGPH/+. FG. AB1Gal4, tGPH/+ and UAS-dPIP4K^RNAi^/+; AB1Gal4, tGPH/+.

[Figure 5](#F5){ref-type="fig"} - B, C. AB1Gal4/+ and AB1Gal4; UAS-dINR^RNAi^. D(i). AB1Gal4/+ and UAS-dINR/+; AB1Gal4/+ and (ii). AB1Gal4/+; dPIP4K^29^ and UAS-dINR/+; AB1Gal4/+; dPIP4K^29^. E(i). AB1Gal4/+ and UAS-Chico/+; AB1Gal4/+ and (ii). AB1Gal4/+; dPIP4K^29^ and UAS-Chico/+; AB1Gal4/+; dPIP4K^29^. F(i). AB1Gal4/+ and UAS-PDK1^A467V^/+; AB1Gal4/+ and (ii). AB1Gal4/+; dPIP4K^29^ and UAS-PDK1^A467V^/+; AB1Gal4/+; dPIP4K^29^. H. Act5cGal4/+. I. Act5CGal4/+; UAS-dPIP4K; dPIP4K^29^. J. Act5CGal4/+; dPIP4K^29^. K. Act5CGal4/+; UAS- dPIP4K^KinaseDead^; dPIP4K^29^.

Method Details {#S16}
--------------

### DNA constructs and transgenic flies {#S17}

For PIP~3~ measurements in the *dPIP4K^29^* rescue experiment ([Figure 2A](#F2){ref-type="fig"}) using GFP-PH-GRP1 probe, we cloned dPIP4K cDNA (BDGP clone\# LD10864) into pUAST-attB between EcoRI and *XhoI* sites without any tag. The generation of flies expressing dPIP4K::mCherry-CAAX was first described in ([@R28]). Briefly, we amplified the mCherry-CAAX fragment from pcDNA3-mCherry-CAAX. We used GIBSON assembly to insert the mCherry--CAAX sequence at the C-terminal of PIP4K after a flexible linker sequence (GGSGGGSGGGSG) by introducing overlaps during the PCR step. Similarly, for targeting dPIP4K to the endomembranes, the sequence QGSMGLPCVVM ([@R48]) replaced the CAAX motif in the dPIP4K::mCherry-CAAX construct. To generate Lysosomal-dPIP4K::eGFP, the 39 amino-acid sequence from p18/LAMTOR ([@R38]) was used as a signal sequence. The signal sequence was commercially synthesized with a C-terminal flag tag and introduced upstream of dPIP4K::eGFP. The entire fusion construct was cloned into pUAST-attB by GIBSON assembly using *NotI* and *XbaI* sites. The constructs were transfected in S2R+ cells using Effectene as per manufacaturer's protocol and their localization was confirmed by imaging using a 60X objective on a Olympus FV 3000 confocal microscope. Site-directed mutation to generate kinase dead dPIP4K (Aspartic acid at position 271 mutated to Alanine) was introduced through PCR amplification of the plasmid containing the wild-type untagged dPIP4K gene, using primers containing the desired mutation in the middle flanked on either side by exactly complementary nucleotides. All molecular constructs were conceptualized and analyzed further with use of the molecular cloning tools available on the free online platform -- [Benchling.com](https://www.benchling.com/). The transgenic lines were generated by site-specific recombination in transgenic parent lines containing attP sites. It was noted that the the level of GFP fluorescence from lysosomal-dPIP4K::eGFP was observed to be very low in the salivary glands and did not interfere with our analysis PIP~3~ measurements using the GFP::PH-GRP1 probe in [Figure 3D](#F3){ref-type="fig"}. Using GIBSON assembly, we added a C-terminal CAAX motif to the PIP4K2B fragment amplified from PIP4K2B::eGFP (kind gift from Jonathan Clarke, Uni. Of Cambridge) and cloned the fusion construct into pEGFP-C1 vector between *NheI* and BamHI sites to generate PIP4K2B::mCherryCAAX. The localization of PIP4K2B::eGFP and PIP4K2B::mCherryCAAX was confirmed using confocal microscopy as described before. All primer sequences used for cloning are available on request.

### mRNA quantification using qPCR analysis {#S18}

RNA from 3 wandering third instar larvae was extracted using standard TRIzol -- chloroform method. cDNA was synthesized from 1 μg of RNA using Superscript II reverse transcriptase (Invitrogen). A no reverse transcription control sample was also included for each genotype. qPCR analysis was performed on an Applied Biosystems 7500 fast qPCR system using diluted cDNA samples and primers against genes of interest and *rp49* as internal controls. The C~t~ values obtained for different genes were normalized to those of *rp49* from the same sample.

### Cell Culture, RNAi and Insulin stimulation {#S19}

CHO cell line stably expressing insulin receptor (isoform A) was a kind gift from Dr Nicholas Webster, UCSD. These were maintained at standard conditions in HF12 culture medium supplemented with 10% Foetal bovine serum and under G418 selection (400 μg/ml). Transfections were done 48 hr. before the assay using FuGene as per manufacturer's protocols when the cultures were 50% confluent. For insulin stimulation assays, cells were starved overnight in HF12 medium without serum. Thereafter, the cells were de-adhered, collected into eppendorf tubes and stimulated with 1 μM insulin for indicated times. Post stimulation, cells were spun down and lysed immediately.

S2R+ cells were cultured in Schneider's medium supplemented with 10% non-heat inactivated fetal bovine serum and contained antibiotics -- streptomycin and penicillin. dsRNA was synthesized in-house using Megascript RNAi Kit as per manufacturer's instructions. For dsRNA treatments, 0.5 X 10^6^ cells were seeded into a 24-well plate. Once observed to be settled, cells were incubated with incomplete medium containing 1.875 μg of dsRNA. After 1 hour, an equal amount of complete medium was added to each well. The same procedure was repeated on each well 48 hours after initial transfection after removal of the spent medium from each well. Cells were harvested by trypsinization after a total of 96 hours of dsRNA treatment. For mass spectrometric estimation of PIP~3~, S2R+ cells were pelleted down and stimulated with 1 μM insulin for 10 min after a short 20 min starvation. The reaction was stopped by the addition of ice-cold initial organic mix (described later in the section) and used for lipid extraction.

### Larval growth curve analysis {#S20}

Adult flies were made to lay eggs within a span of 4-6 hr on normal food. The protocol followed for transfer of larvae onto vials containing different diets is described in [Figures S6A and S6D](#SD1){ref-type="supplementary-material"}. For experiment indicated in [Figure S6B](#SD1){ref-type="supplementary-material"}, vials had around 15-25 larvae. For the experiment depicted in [Figures 5H--5K](#F5){ref-type="fig"}, the vials had about 7-10 larvae. The values for pupariation were plotted after normalizing to the maximum percentage of pupariation achieved in each vial. For data in [Figure S6B](#SD1){ref-type="supplementary-material"}, mean pupariation percentage was calculated for each time bin and plotted with SD as errors. For [Figures 5H--5K](#F5){ref-type="fig"}, every measurement was plotted and thereafter fitted to a variable slope on Graph Pad Prism (ver. 5)

### Hemolymph Trehalose Measurements {#S21}

The measurements were done as first described in [@R39]. Hemolymph was pooled from five to eight larvae to obtain 1 μL for assay. 1 μl hemolymph was diluted in 25 μl 0.25 M Sodium Bicarbonate and heated at 95°C for 2 hr, brought down to room temperature. Further, 66 μl of 0.25 M sodium acetate and 8 μl 1M acetic acid was added to the 25 μl from the previous step to form the digestion mix. 40 μl of this mix was digested with 1 μl of Porcine Trehalase at 37°C overnight. The concentration of digested trehalose was measured from 10 μl of digested sample against glucose standards using the glucose (GO) assay kit.

### Cell size analysis in salivary glands {#S22}

Salivary glands were dissected from wandering third instar larvae and fixed in 4% paraformaldehyde for 30 min at 4°C. Post fixation, glands were washed thrice with 1X PBS and incubated in BODIPY-FL-488 for 3 hours at room temperature. The glands were washed thrice in 1X PBS following which nuclei were labeled (using either DAPI or TOTO3) for 10 mins at room temperature and washed with 1X PBS again. The glands were then mounted in 70% glycerol and imaged within a day of mounting. Imaging was done on Olympus FV1000 Confocal LSM using a 20x objective. The images were then stitched into a 3D projection using an ImageJ plugin. These reconstituted 3D z stacks were then analyzed for nuclei numbers (correlate for cell number) and volume of the whole gland using Volocity Software (version 5.5.1, Perkin Elmer Inc.). The average cell size was calculated as the ratio of the average volume of the gland to the number of nuclei.

### Imaging PIP~3~ probe in larval tissues {#S23}

For experiments with salivary glands, wandering third instar larvae were dissected one larva at a time and glands were immediately dropped into one well of a 96-well plate containing either only PBS or PBS + 10 μM Insulin (75 μl) and incubated for 10 min at room temperature. Following this, 25 μl of 16% PFA was added into the same well to yield a final conc. of 4% PFA. The glands were fixed in this solution for 15 min at room temperature and then transferred sequentially to wells containing PBS every 10 min for 3 washes. Finally, glands were mounted in 80% glycerol in PBS containing antifade (0.4% propyl-gallate). For experiments with fat body lobes, late third instar feeding larvae were starved by placing them on a filter paper soaked in 1X PBS for 2 hr. Thereafter, the incubation, fixation and mounting steps were done exactly as described for salivary glands. Imaging was done on LSM 780 inverted confocal microscope with a 20X/0.8 NA Plan Apochromat objective.

For live imaging, salivary glands from wandering third instar larvae were dissected (glands from one larva imaged in one imaging run) and placed inside a drop of imaging buffer (1X PBS containing 2mg/ml glucose) on a coverglass. The buffer was slowly and carefully soaked out with a paper tissue to let the glands settle and adhere to the surface. Thereafter, the glands were immediately rehydrated with 25 μl of imaging buffer. The imaging was done on Olympus FV3000 LSM confocal system using a 10X objective. A total of 80 frames of a single plane were acquired at 10 s intervals. While imaging, 25 μl of 20uM (2X) bovine insulin was used to stimulate the glands. After the steady state was achieved, 50 μl of 800nM (2X) of wortmannin was added on top to inhibit PI3K activity.

### Immunostaining of larval brains {#S24}

Brains were dissected out from wandering third instar larvae in 1X PBS and fixed in 4% Paraformaldehyde for 30 min at room temperature, permeabilised with 0.3% Triton X-100 solution in PBS (0.3% PBTx) and incubated overnight with dILP2 antibody at 1:200 dilution. Following day, the brains were washed thrice in 0.3% PBTx and incubated with Alexa fluor-conjugated secondary antibody (Thermo Scientific Inc., 1:200 dilution) for 4 hr at room temperature. Following this, DAPI staining was done for 10 min. The brains were again washed extensively in 0.3% PBTx, mounted in 70% Glycerol and imaged on the Zeiss LSM 780 confocal microscope using the 20X objective.

### LCMS based PIP~2~ and PIP~3~ measurements {#S25}

To test if the probe-based imaging of PIP~3~ in single cells indeed reflects *in vivo* changes across the animal, we refined and adapted existing protocols ([@R11]) to perform mass spectrometric measurements of PIP~3~ from *Drosophila* S2R+ cells and whole larval lipid extracts (Scheme depicted in [Figure S1E](#SD1){ref-type="supplementary-material"}). The amount of PIP~3~ that has been detected and quantified from biological samples is in the range of a few tens of picomoles ([@R36]). We coupled liquid chromatography to high sensitivity mass spectrometry (LCMS) and used a Multiple Reaction Monitoring (MRM) method to detect PIP~3~ standards for reliable quantification down to a few femtomoles (ca. 10 fmol, the lowest point in the figure inset on the standard curve in [Figure S1D](#SD1){ref-type="supplementary-material"}. Since cellular lipids are composed of molecular species with varying acyl chain lengths, we first characterized the PIP~3~ species from *Drosophila* whole larval extracts through use of neutral loss scans and thereafter quantified the abundance of these species. [Figure S1F](#SD1){ref-type="supplementary-material"} depicts the elution profiles of the different PIP~3~ species from *Drosophila* larvae that were reproducibly detected across samples and [Figure S2Ai](#SD1){ref-type="supplementary-material"} shows the relative abundance of various PIP~3~ species. The 34:2 PIP~3~ species was found to be the most abundant. To standardize the procedure, we bisected whole larvae, stimulated them with insulin and measured the levels of various PIP~3~ species between samples with and without insulin stimulation. Our LCMS method could clearly detect an increase in the levels of all the identified PIP~3~ species upon insulin stimulation ([Figure S2Aii](#SD1){ref-type="supplementary-material"}). Similar process was followed for identification and characterization of PIP~3~ species from S2R+ cells and the identification of PIP~2~ from both S2R+ cells and larval samples. A detailed description of the steps involved in the whole procedure is given below:

### Lipid extraction {#S26}

5 larvae were dissected in 1X PBS (or cells pelleted from a single well) and transferred immediately into 37.5 μl of 1X PBS in a 2 mL Eppendorf. For insulin stimulation, to this, 37.5 μl of 100 μM Insulin for larval samples (final concentration -- 50 μM) and 2 μM Insulin for cells (final concentration -- 1 μM) was added and the tube was incubated on a mix mate shaker for 10 min at 500 rpm. At the end of incubation time, 750 μl of ice-cold 2:1 MeOH:CHCl~3~ organic mix was added to stop the reaction. In the case of larval samples, part of this solution was decanted and the rest of the mix containing larval tissues was transferred into a homogenization tube. Larval tissues were homogenized in 4 cycles of 10 s with 30 s intervals at 6000 rpm in a homogenizer (Precellys, Bertin Technologies). The tubes were kept on ice at all intervals (No homogenization was required for cell culture samples). The entire homogenate was then transferred to a fresh eppendorf and the homogenization tube was then washed with the decanted mix kept aside earlier. 120 μl of water was added to the homogenate collected in eppendorf, followed by the addition of 5 ng of 17:0, 20:4 PIP~3~ internal standard (ISD). The mixture was vortexed and 725 μl of chloroform was added to it. After vortexing again for 2 min at around 1000-1500 rpm, the phases were separated by centrifugation for 3 min at 1500 g. 1ml (1.2 mL for cells) of the lower organic phase was removed and stored in a fresh tube. In the case of larval samples, to the remaining aqueous upper phase, 725 μl of chloroform was again added. The mixture was vortexed and spun down to separate the phases. Again, 1 mL of the organic phase was collected and pooled with the previous collection (total of 2ml). (For cell culture samples, only one round of neutral lipid extraction is sufficient). This organic phase was used for measuring total organic phosphate. To the aqueous phase, 500 μl of the initial organic mix was added followed by 170 μl of 2.4M HCl and 500 μl of CHCl~3~. This mixture was vortexed for 5 min at 1000-1500 rpm and allowed to stand at room temperature for 5 minutes. The phases were separated by centrifugation (1500 g, 3 min). The lower organic phase was collected into a fresh tube by piercing through the protein band sitting at the interface. To this, 708 μl of lower phase wash solution was added, the mixture was vortexed and spun down (1500 g, 3 min). The resultant lower organic phase was completely taken out carefully into an Eppendorf tube and used for derivatization reaction.

### Extraction solvent mixtures {#S27}

Initial organic mix: MeOH/Chloroform in the ratio of 484/242 ml, Lower Phase Wash Solution: Methanol/1 M hydrochloric acid/ chloroform in a ratio of 235/245/15 ml. All ratios are expressed as vol/vol/vol.

### Derivatization of Lipids {#S28}

To the organic phase of the sample, 50 μl of 2M TMS-Diazomethane was added (TO BE USED WITH ALL SAFETY PRECAUTIONS!). The reaction was allowed to proceed at room temperature for 10 min at 600 rpm. After 10 min, 10 μl of Glacial acetic acid was added to quench the reaction, vortexed briefly and spun down. 700 μl of post derivatization wash solvent was then added to the sample, vortexed (2 min, 1000-1500 rpm) and spun down. The upper aqueous phase was discarded and the wash step was repeated. To the final organic phase, 100 μl of 9:1 MeOH:H~2~O mix was added and the sample was dried down to about 10-15 μl in a speedvac under vacuum.

### Chromatography and Mass spectrometry {#S29}

The larval lipid extracts were re-suspended in 170 μl LC-MS grade methanol and 30 μl LC-MS grade water (80 μl methanol and 20 ul water for cell culture samples). Samples were injected as duplicate runs of 3.5 (stimulated) or 7 μl (unstimulated) for PIP~3~ measurements and 2 ul injections for PIP~2~ measurements. Chromatographic separation was performed on an Acquity UPLC BEH300 C4 column (100 × 1.0 mm; 1.7 μm particle size) purchased from Waters Corporation, USA on a Waters Aquity UPLC system and detected using an ABSCIEX 6500 QTRAP mass spectrometer. The flow rate was 100 μL/min. Gradients were run starting from 55% Buffer A (Water + 0.1% Formic Acid)- 45% Buffer B (Acetonitrile + 0.1% Formic acid) from 0-5 min; thereafter 45% B to 100% B from 5-10 min; 100% B was held from 10-15 min; brought down from 100% B to 45% B between 15-16 min and held there till 20th min to re-equilibrate the column. On the mass spectrometer, in pilot standardization experiments, we first employed Neutral Loss Scans on biological samples to look for parent ions that would lose neutral fragments of 598 a.m.u indicative of PIP~3~ lipid species and 490 a.m.u indicative of PIP~2~ species (as described in ([@R11])). Thereafter, these PIP~2~ and PIP~3~ species were quantified in biological samples using the selective Multiple Reaction Monitoring (MRM) method in the positive mode. For PIP~3~, only those MRM transitions that showed an increase upon insulin stimulation of biological samples were used for the final experiments (depicted in [Figure S2Aii](#SD1){ref-type="supplementary-material"}). Area of all the peaks was calculated on Sciex MultiQuant software. The area of the internal standard peak was used to normalize for lipid recovery during extraction. The normalized area for each of the species was then divided by the amount of organic phosphate measured in each of the biological samples. The other mass spectrometer parameters are as follows:

For PIP~3~, ESI voltage: +5100 V; Dwell time: 60-65 ms; DP (De-clustering Potential): 35.0 V; EP: (Entrance Potential): 10.1 V, CE (Collision Energy): 47.0-50.0 V; CXP (Collision cell Exit Potential): 11.6-12.0 V, Source Temperature: 350 C, Curtain Gas: 35.0, GS1: 15, GS2: 15.

For PIP~2~, ESI voltage: +5100-5200 V; Dwell time: 35-65 ms; DP (De-clustering Potential): 60.0 V; EP: (Entrance Potential): 11.0 V, CE (Collision Energy): 37.0 V; CXP (Collision cell Exit Potential): 15.0 V, Source Temperature: 300 C, Curtain Gas: 35-37.0, GS1:15-20, GS2: 15-20.

The MRM mass pairs used for PIP~2~ and PIP~3~ species identification and quantification are listed below:

                    Sample                                                          
  ----------------- -------- -------- -------- ------- ---------- -------- -------- -------
  MRM Transitions   32_1     1147.5   1039.5   549.5   30_1       1119.5   1011.5   521.5
                                                                                    
                    32_2     1145.5   1037.5   547.5   30_3       \-       1007.5   517.5
                                                                                    
                    34_1     1175.5   1067.5   577.5   30_4       \-       1005.5   515.5
                                                                                    
                    34_2     1173.5   1065.5   575.5   32_0       1149.5   1041.5   551.5
                                                                                    
                    34_3     1171.5   1063.5   573.5   32_1       1147.5   1039.5   549.5
                                                                                    
                    36_1     1203.5   1095.5   605.5   32_2       1145.5   1037.5   547.5
                                                                                    
                    36_2     1201.5   1093.5   603.5   32_3       \-       1035.5   545.5
                                                                                    
                    36_3     1199.5   1091.5   601.5   34_0       1177.5   1069.5   579.5
                                                                                    
                    36_4     1197.5   1089.5   599.5   34_1       1175.5   1067.5   577.5
                                                                                    
                                                       34_2       1173.5   1065.5   575.5
                                                                                    
                                                       34_3       1171.5   1063.5   573.5
                                                                                    
                                                       34_4       1169.5   1061.5   571.5
                                                                                    
                                                       34_5       1167.5   1059.5   569.5
                                                                                    
                                                       36_0       \-       1097.5   607.5
                                                                                    
                                                       36_1       \-       1095.5   605.5
                                                                                    
                                                       36_2       1201.5   1093.5   603.5
                                                                                    
                                                       36_3       1199.5   1091.5   601.5
                                                                                    
                                                       36_4       1197.5   1089.5   599.5
                                                                                    
                                                       36_5       1195.5   1087.5   597.5
                                                                                    
                                                       38_0       \-       1125.5   635.5
                                                                                    
                                                       38_2       \-       1121.5   631.5
                                                                                    
                                                       38_3       1227.5   1119.5   629.5
                                                                                    
                                                       38_4       1225.5   1117.5   627.5
                                                                                    
                                                       38_5       1223.5   1115.5   625.5
                                                                                    
                                                       37_4 ISD   1211.5   \-       613.5

### Total Organic Phosphate measurement {#S30}

800 μl (larval samples) or 1 mL (cell samples) of the organic phase from each sample was taken into phosphate-free glass tubes and dried completely at 90°C. Tubes containing phosphate standard (KH~2~PO~4~ -- 7.34 mM stock) in the range of 3.67 nmol to 198.18 nmol were also dried at 120°C. After the addition of 50 μl of 70% perchloric acid was to all the tubes containing the standards and samples, the tubes were heated at 180°C for 30 min and thereafter cooled to room temperature. This was followed by the addition of 250 μl water, 50 μl of 2.5% Ammonium molybdate and 50 μl of 10% Ascorbic acid into each tube and incubation at 37°C for 1 h. The absorbance of the solution in each tube was measured using 130 μl of each sample at 630 nm.

### *In vitro* PI5P4-kinase assay with cell lysates {#S31}

The S2R+ cells were pelleted at 1000 g for 10 min and washed with ice-cold PBS Twice. Thereafter, cells were homogenized in lysis buffer containing 50mM Tris-Cl, pH -- 7.5, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 50mM NaF, 0.27 M Sucrose, 0.1% β-Mercaptoethanol with freshly added protease and phosphatase inhibitors (Roche). The lysate was then centrifuged at 1000 g for 15 min at 4°C. Protein estimation was performed using the Bradford reagent according to the manufacturer's instructions.

Vacuum-dried substrate lipid (6 μM PI5P) and 20 μM of phosphatidylserine were resuspended in 10 mM Tris pH 7.4 and micelles were formed by sonication for 2 min in a bath-sonicator. 50 μl of 2 x PIP-kinase reaction buffer (100 mM Tris pH 7.4, 20 mM MgCl~2~, 140 mM KCl, and 2 mM EGTA) containing 20 μM ATP, 5 μCi \[γ-^32^P\] ATP and cell lysates containing \~10 μg total protein was added to the micelles. The reaction mixture was incubated at 30°C for 16 h. Lipids were extracted and resolved by one-dimensional TLC (45:35:8:2 chloroform: methanol: water: 25% ammonia). The resolved lipids were imaged using phosphorImager.

### Western Blotting {#S32}

For larval western blots, lysates were prepared by homogenizing 3 wandering third instar larvae or 5 pairs of salivary glands from wandering third instar larvae. In the case of CHO-IR and S2R+ cells, pelleted cells were lysed by repeated pipetting in lysis buffer (same as described above). Thereafter, the samples were heated at 95°C with Laemli loading buffer for 5 min and loaded onto an SDS- Polyacrylamide gel. The proteins were subsequently transferred onto a nitrocellulose membrane and incubated with indicated antibodies overnight at 4°C (for actin/tubulin incubation was done at room temperature for 3 hr.). For stripping and re-probing, blots were incubated in a total of 30 mL 3% Glacial acetic acid over 1 hr (10 mL X 3 times, 20 min each), washed extensively \[1 hr, 4 X10ml of Tris Buffer Saline containing 0.1% Tween-20 (0.1% TBST)\], incubated in blocking solution again for 15 min and thereafter re-probed with next primary antibody. Primary antibody concentrations used were -- anti - α-actin, 1:1000; anti- dPIP4K, 1:1000; anti -- GAPDH, 1:1000; anti - PIP4KB, 1:1000; anti -- pAKT^T308^, 1:1000; anti-AKT, 1:1000; anti-pAKT^T342^, 1:1000; anti-pS6K^T398^, 1:1000. The blots were then washed thrice with 0.1% TBS-T and incubated with 1:10000 concentration of appropriate HRP-conjugated secondary antibodies (Jackson Laboratories, Inc.) for 1.5 hr. After three washes with 0.1% TBS-T, blots were developed using Clarity Western ECL substrate (Biorad) on a GE ImageQuant LAS 4000 system.

Quantification and Statistical Analysis {#S33}
---------------------------------------

### PIP~3~ quantification from imaging experiments {#S34}

Confocal slices were manually curated to generate maximum z-projections of middle few planes of cells. Thereafter, line profiles were drawn across clearly identifiable plasma membrane regions and their adjacent cytosolic regions and ratios of mean intensities for these line profiles were calculated for each cell. For salivary glands, about cells from multiple glands were analyzed and used to generate statistics. For fat body, about cells inmany regions from multiple animals were used for analysis.

### PIP~3~ quantification from mass spectrometry measurements {#S35}

The area under the peaks for individual lipid species was extracted using MultiQuant software. Numerical analysis was done in Microsoft Excel. The area was normalized to the value of organic phosphate recovered from the sample.

### Densitometry analysis of western blots {#S36}

Analysis was performed using the ImageJ software. First, the background intensities were subtracted from the images using an average of mean background intensities of a few ROIs adjacent to band of interest. Thereafter, ROIs were drawn around the bands of interest and the integrated intensity of each ROI was extracted from the image. The loading control bands were analyzed in the same manner. Further numerical analyses to obtain ratios of different band intensities were performed in Microsoft Excel.

### Sampling and Statistical analysis {#S37}

Each experiment was performed unblinded on different biological groups with multiple biological replicates. No statistical analysis was done *a priori* to determine the sample sizes. For most comparisons, with the range of sample sizes the experiments could be performed with at a given time, it was not possible to be sure of the normality of distribution. Hence, the non-parametric *Mann-Whitney Test* was used to compare the differences in medians of sample populations. For mass spectrometric lipid measurements from larvae done using three biological replicates per genotype, *Student's t test* was used to check for differences in means between samples of different genotypes ([Figures 1C and 1F](#F1){ref-type="fig"}). One-way ANOVA with post hoc Tukey's pairwise comparison was used whenever the experiment consisted of more than two biological groups.

Supplementary Material {#SM}
======================

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2019.04.084>.
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###### Highlights

-   *Drosophila* PIP4K mutant larvae have increased PIP~3~ levels in cells

-   Cells show enhanced sensitivity to insulin in the absence of PIP4K

-   PIP4K regulates enzymes involved in PIP~3~ turnover at the plasma membrane

-   Loss of PIP4K suppresses insulin resistance phenotypes

![Loss of PIP4K Increases PIP~3~ Levels\
(A and B) Representative confocal images with the distribution and quantification of PIP~3~ levels using GFP::PH-GRP1 probe in (Ai and Aii) larval salivary glands and (Bi and Bii) larval fat body. Scale bars: 50 μm in salivary gland images; 10 μm in fat body images.\
(C) Total PIP~3~ levels using LCMS in whole larval lipid extracts.\
(D) Confocal z-projections depicting PIP~3~ levels in (i and ii) insulin-stimulated (10 μM insulin, 10 min) salivary glands.\
(E) Fat body lobes stimulated with 0.1, 1, and 10 μM insulin after 2-h starvation. Scale bars: 50 μm. (iii) Mean fold change in response to insulin (from data in ii).\
(F) Total PIP~3~ levels using LCMS in insulin-stimulated whole larval lipid extracts.\
Boxplots with whiskers at minimum and maximum values, a line at the median, and scatterplots with mean ± SD are shown. Numbers in parentheses below the plots indicate the number of biological replicates. Statistical tests: (A, B, and D) Mann-Whitney test and (C, E, and F) Student's unpaired t test. \*p value \< 0.05. See also [Figures S1 and S2](#SD1){ref-type="supplementary-material"}.](EMS83416-f001){#F1}

![dPIP4K Cell-Autonomously Controls PIP~3~ Levels\
PIP~3~ levels in salivary glands.\
(A) Mutant and wild-type dPIP4K rescue.\
(B) Control, mutant, and kinase-dead dPIP4K rescue.\
(C) (i) Immunoblot (from wandering third instar larvae) showing salivary gland-specific depletion of dPIP4K (*dPIP4K^RNAi^*). (ii) PIP~3~ levels in control and *dPIP4K^RNAi^* salivary glands.\
(D) (i) Immunoblot for dPIP4K knockdown in S2R^+^ cells with two different dsRNAs. (ii) Total PIP~3~ using LCMS in whole cell lipid extracts of S2R^+^ cells treated with indicated dsRNAs (data pooled from two experiments, a total of four biological replicates). Scatter plots with mean ± SD. Statistical test: one-way ANOVA with post hoc Tukey's multiple pairwise comparison. \*p value \< 0.05; \*\*p value \<0.01.\
(E) Western blots for (i) pAKT^T342^ and (ii) pS6K^T398^ levels in control and dPIP4K knockdown cells.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](EMS83416-f002){#F2}

![PIP4K Acts at the Plasma Membrane to Regulate Insulin-Stimulated PIP~3~ Production\
(A) Constructs targeting dPIP4K to different subcellular compartments.\
(B) Confocal z-projections of S2R+ cells expressing (i) wild-type dPIP4K::eGFP, (ii) lysosome-targeted dPIP4K::GFP (Lyso-dPIP4K::eGFP), and dPIP4K::mCherry targeted to (iii) endomembranes (dPIP4K::mCherry^EM−^ ER, Golgi, and endo-lysosomal system) and (iv) plasma membrane (dPIP4K::mCherry^CAAX^).\
(C) (i) Immunoblots from S2R+ lysates expressing indicated *dPIP4K* constructs used in the *in vitro* assay. (ii) *In vitro* PIP-kinase assay for different *dPIP4K* constructs from S2R+ cell lysates.\
(D--G) PIP~3~ measurement using the PH-GFP-GRP1 probe in insulin-stimulated (10 μM) *dPIP4K^29^* salivary glands reconstituted with (D) Lyso-dPIP4K::eGFP, (E) dPIP4K::mCherry^EM^, and (F) dPIP4K::mCherry^CAAX^, and (G) overexpression of wild-type dPIP4K and dPIP4K::mCherry^CAAX^.\
(H) (i) Representative confocal z-projections of CHO-IR cells expressing GFP-PIP4K2B and PIP4K2B::mCherry-CAAX. Scale bars: 10 μm. (ii) Immunoblots for pAKT from insulin-stimulated (1 μM, 10 min) CHO-IR cells.\
Numbers below the blots are mean pAKT/Tot-AKT ratios from three independent experiments. Boxplots with whiskers at minimum and maximum values and a line at the median are shown. Numbers in parentheses below the plots indicate the number of biological replicates. Statistical tests: (D--G) one-way ANOVA with post hoc Tukey's multiple pairwise comparison. \*p value \< 0.05; \*\*p value \< 0.01. See also [Figures S3 and S4](#SD1){ref-type="supplementary-material"}.](EMS83416-f003){#F3}

![dPIP4K Alters PIP~3~ Turnover by Limiting Class I PI3K Activity\
(A) (i) Reactions influencing PIP~3~ turnover at the plasma membrane. Insulin activates PI3K, and wortmannin irreversibly inhibits PI3K. (ii) Three phases in the live-imaging assay to follow PIP~3~ dynamics.\
(B) Single live-imaging traces of plasma membrane/cytosolic PIP~3~ probe fluorescence ratio from salivary glands expressing GFP::PH-GRP1.\
(C and D) Comparison of average live-imaging traces of PIP~3~ probe fluorescence ratios in (C) control and *dPIP4K^29^*, and (D) control and *dPIP4K* overexpression salivary glands (N = 7 imaging runs for all genotypes, minimum of about nine cells analyzed from each run). Error bars: SD. Controls were repeated as the two experiments were performed at different times.\
(E) Normalized differences in instantaneous rate of change in fluorescence (ratio of test to that in controls); maximal difference is indicated alongside.\
(F) PIP~3~ levels in wild-type and dPIP4K-overexpressing salivary glands. Live salivary gland PIP~3~ dynamics upon knockdown of dPIP4K.\
See also [Figure S5](#SD1){ref-type="supplementary-material"}.](EMS83416-f004){#F4}

![dPIP4K Interacts with Insulin Receptor Signaling *In Vivo* to Modulate Larval Physiology\
(A) Components of insulin signaling cascade used in the study.\
(B and C) Salivary gland (SG) cell size measurements (B) and quantification of the number of nuclei (C) upon knockdown of insulin receptor in salivary glands.\
(D--G) SG cell size measurements in wild-type (*ROR*) and *dPIP4K^29^* backgrounds upon (D) overexpression of dInR, (E) overexpression of Chico, (F) overexpression of PDK1^A467V^, and (G) change in median SG cell sizes across different genetic manipulations.\
(H--K) Percentage pupariation over time (after egg laying \[AEL\]) for genotypes - (H) Act\>, (I) *Act\>dPIP4K^WT^; dPIP4K^29^*, (J) *Act\>; dPIP4K^29^*, and (K) *Act\>dPIP4K^KinaseDead^; dPIP4K^29^* on normal (ND) and high-sugar (HSD) diets. GraphPad Prism used to fit a variable slope curve for each genotype. Numbers indicate the time ± 95% confidence interval (CI) (h) at 50% pupariation. Boxplots with whiskers at minimum and maximum values and a line at the median are shown. Numbers in parentheses on the plots indicate number of biological replicates.\
Statistical tests: (B--F) Mann-Whitney test. *\*\**p value \< 0.01; \*\*\*p value \< 0.001. See also [Figure S6](#SD1){ref-type="supplementary-material"}.](EMS83416-f005){#F5}

[^1]: Lead Contact
